{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(1)"],"submitter":["Yang Y"],"pubmed_abstract":["The persistent emergence of SARS-CoV-2 variants continues to compromise current vaccine efficacy, driving the development of broad-spectrum coronavirus vaccines to address variant evasion and future outbreaks. To develop a pan-coronavirus vaccine, we identified some conserved T/B epitopes across spike proteins of human-infecting coronaviruses, focusing on two conserved long peptides, VV and VS, which demonstrated broad immunogenicity in PBMCs from COVID-19 convalescent patients. By structurally fusing the VV and VS long peptides with heptad repeat 1/2 (HR1/2) domains from the S2 subunit, we engineered a trimeric immunogen HR1-VV-HR2-VS. This design induced superior cellular and humoral immune responses compared to individual peptide components in immunized mice. The vaccine also significan"],"journal":["Emerging microbes & infections"],"pagination":["2631206"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12927409"],"repository":["biostudies-literature"],"pubmed_title":["Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes."],"pmcid":["PMC12927409"],"pubmed_authors":["Hong M","Yao J","Lu X","Ding C","Li E","Xing Y","He H","Jin T","Feng F","Wang J","Ye X","Yang Y","Tan W","Cheng Q","Huang X","Zhao G","Shang Y","Chen Y","Zou R","Li B","Chiu S","Huang B","Tang Y","Tong D"],"additional_accession":[]},"is_claimable":false,"name":"Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.","description":"The persistent emergence of SARS-CoV-2 variants continues to compromise current vaccine efficacy, driving the development of broad-spectrum coronavirus vaccines to address variant evasion and future outbreaks. To develop a pan-coronavirus vaccine, we identified some conserved T/B epitopes across spike proteins of human-infecting coronaviruses, focusing on two conserved long peptides, VV and VS, which demonstrated broad immunogenicity in PBMCs from COVID-19 convalescent patients. By structurally fusing the VV and VS long peptides with heptad repeat 1/2 (HR1/2) domains from the S2 subunit, we engineered a trimeric immunogen HR1-VV-HR2-VS. This design induced superior cellular and humoral immune responses compared to individual peptide components in immunized mice. The vaccine also significan","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Dec","modification":"2026-07-16T18:30:44.043Z","creation":"2026-07-11T03:08:37.337Z"},"accession":"S-EPMC12927409","cross_references":{"pubmed":["41672103"],"doi":["10.1080/22221751.2026.2631206"]}}